Page 137 - Read Online

Ibrahim et al ALDHs and prostate cancer

structure illuminates function. Cell 2002;108:453-63. Aldehyde dehydrogenase 1A3 is transcriptionally activated by all-
145. Dilworth FJ, Chambon P. Nuclear receptors coordinate the activities trans-retinoic acid in human epidermal keratinocytes. Biochem
of chromatin remodeling complexes and coactivators to facilitate Biophys Res Commun 2010;400:207-11.
initiation of transcription. Oncogene 2001;20:3047-54. 161. Sullivan KE, Cerione RA, Wilson KF. ALDH1A3 in CSCs. Aging
146. Tsagozis P, Augsten M, Pisa P. All trans-retinoic acid abrogates the (Albany NY) 2017;9:1351-2.
pro-tumorigenic phenotype of prostate cancer tumor-associated 162. Sullivan KE, Rojas K, Cerione RA, Nakano I, Wilson KF. The stem
macrophages. Int Immunopharmacol 2014;23:8-13. cell/cancer stem cell marker ALDH1A3 regulates the expression of
147. Fontanelli BA, Chuffa LG, Teixeira GR, Amorim JP, Mendes LO, the survival factor tissue transglutaminase, in mesenchymal glioma
Pinheiro PF, Kurokawa CS, Pereira S, Favaro WJ, Martins OA, Mello stem cells. Oncotarget 2017;8:22325-43.
Junior W, Martinez M, Junior AR, Martinez FE. Chronic ethanol 163. Li Y, Wang L, Ai W, He N, Zhang L, Du J, Wang Y, Mao X, Ren J,
consumption alters all-trans-retinoic acid concentration and expression Xu D, Zhou B, Li R, Mai L. Regulation of retinoic acid synthetic
of their receptors on the prostate: a possible link between alcoholism enzymes by WT1 and HDAC inhibitors in 293 cells. Int J Mol Med
and prostate damage. Alcohol Clin Exp Res 2013;37:49-56. 2017;40:661-72.
148. Hammond LA, Van Krinks CH, Durham J, Tomkins SE, Burnett RD, 164. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X,
Jones EL, Chandraratna RA, Brown G. Antagonists of retinoic acid Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J,
receptors (RARs) are potent growth inhibitors of prostate carcinoma Moscatelli D, Wilson EL. Molecular signatures of prostate stem cells
cells. Br J Cancer 2001;85:453-62. reveal novel signaling pathways and provide insights into prostate
149. Aboseif SR, Dahiya R, Narayan P, Cunha GR. Effect of retinoic acid cancer. PLoS One 2009;4:e5722.
on prostatic development. Prostate 1997;31:161-7. 165. Polyak K, Weinberg RA. Transitions between epithelial and
150. Nelson CH, Buttrick BR, Isoherranen N. Therapeutic potential of the mesenchymal states: acquisition of malignant and stem cell traits.
inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 Nat Rev Cancer 2009;9:265-73.
by xenobiotics. Curr Top Med Chem 2013;13:1402-28. 166. Thiery JP. Epithelial-mesenchymal transitions in tumour progression.
151. Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, Ekpin Nat Rev Cancer 2002;2:442-54.
E, George A, Zheng Y, Lam HM, Morrissey C, Chung CY, Farias 167. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at
EF, Bernstein E, Aguirre-Ghiso JA. NR2F1 controls tumour cell the crossroads of development and tumor metastasis. Dev Cell
dormancy via SOX9- and RARbeta-driven quiescence programmes. 2008;14:818-29.
Nat Commun 2015;6:6170. 168. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell
152. Roy A, Ramalinga M, Kim OJ, Chijioke J, Lynch S, Byers S, Kumar cooperativity in metastasis. Cancer Res 2009;69:7135-9.
D. Multiple roles of RARRES1 in prostate cancer: autophagy 169. Mol AJ, Geldof AA, Meijer GA, van der Poel HG, van Moorselaar
induction and angiogenesis inhibition. PLoS One 2017;12:e0180344. RJ. New experimental markers for early detection of high-risk
153. Oldridge EE, Walker HF, Stower MJ, Simms MS, Mann VM, Collins prostate cancer: role of cell-cell adhesion and cell migration. J
AT, Pellacani D, Maitland NJ. Retinoic acid represses invasion Cancer Res Clin Oncol 2007;133:687-95.
and stem cell phenotype by induction of the metastasis suppressors 170. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression
RARRES1 and LXN. Oncogenesis 2013;2:e45. that lead to bone metastasis. Int J Cancer 2011;128:2545-61.
154. Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson 171. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch
RR, Hofacker J, Branch RA. A phase II trial of all-trans-retinoic from E-cadherin to N-cadherin expression indicates epithelial
acid in hormone-refractory prostate cancer: a clinical trial with to mesenchymal transition and is of strong and independent
detailed pharmacokinetic analysis. Cancer Chemother Pharmacol importance for the progress of prostate cancer. Clin Cancer Res
1997;39:349-56. 2007;13:7003-11.
155. Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus DM, 172. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF,
Scher HI. The development of biologic end points in patients treated Schaafsma HE, Debruyne FM, Isaacs WB. Expression of the cellular
with differentiation agents: an experience of retinoids in prostate adhesion molecule E-cadherin is reduced or absent in high-grade
cancer. Clin Cancer Res 2000;6:838-46. prostate cancer. Cancer Res 1992;52:5104-9.
156. Nehme A, Varadarajan P, Sellakumar G, Gerhold M, Niedner H, 173. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF,
Zhang Q, Lin X, Christen RD. Modulation of docetaxel-induced Oosterhof GO, Debruyne FM, Schalken JA. Decreased E-cadherin
apoptosis and cell cycle arrest by all- trans retinoic acid in prostate expression is associated with poor prognosis in patients with prostate
cancer cells. Br J Cancer 2001;84:1571-6. cancer. Cancer Res 1994;54:3929-33.
157. Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, 174. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji
Nakanishi O, Sacchi N, Pili R. In vivo imaging of retinoic acid KC. Aberrant expression of E-cadherin and beta-catenin in human
receptor beta2 transcriptional activation by the histone deacetylase prostate cancer. Urol Oncol 2005;23:402-6.
inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate 175. Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen
2005;64:20-8. S, Jones LW, Imam SA. Overexpression of E-cadherin and beta-
158. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. catenin proteins in metastatic prostate cancer cells in bone. Prostate
Annu Rev Pathol 2011;6:345-64. 2008;68:78-84.
159. Marcato P, Dean CA, Liu RZ, Coyle KM, Bydoun M, Wallace M, 176. Verras M, Sun ZJ. Roles and regulation of Wnt signaling and beta-
Clements D, Turner C, Mathenge EG, Gujar SA, Giacomantonio catenin in prostate cancer. Cancer Letters 2006;237:22-32.
CA, Mackey JR, Godbout R, Lee PW. Aldehyde dehydrogenase 1A3 177. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J,
influences breast cancer progression via differential retinoic acid Alanen K, Nees M, Kallioniemi O. FZD4 as a Mediator of ERG
signaling. Mol Oncol 2015;9:17-31. oncogene-induced WNT signaling and epithelial-to-mesenchymal
160. Koenig U, Amatschek S, Mildner M, Eckhart L, Tschachler E. transition in human prostate cancer cells. Cancer Res 2010;70:6735-45.

Journal of Cancer Metastasis and Treatment ¦ Volume 4 ¦ Aug 21, 2018 15